{
    "name": "carbonyl iron",
    "comment": "Rx, OTC",
    "other_names": [
        "Feosol (Carbonyl Fe)",
        "Icar C",
        "Icar Pediatric",
        "Ircon"
    ],
    "classes": [
        "Iron Products"
    ],
    "source": "https://reference.medscape.com/drug/feosol-carbonyl-fe-icar-c-carbonyl-iron-342171",
    "pregnancy": {
        "common": [
            "Pregnancy Category: Not available",
            "Lactation: Excreted in breast milk"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Excreted in breast milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Severe iron toxicity may occur in overdose, especially when ingested by children. ",
                "Nonintentional iron overdose is the leading cause of fatal poisoning in children younger than 6 years. Keep out of reach of children"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Hemochromatosis, hemolytic anemia or anemia not associated with iron deficiency",
                "Peptic ulcer, regional enteritis, ulcerative colitis"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Do not take within 2 hr of oral tetracycline antibiotics",
                "Not for use in patients receiving frequent blood transfusions",
                "Avoid in premature infants until their deficient vitamin E stores at birth are replenished",
                "Avoid administering iron for >6 months except in patients with continuous bleeding or menorrhagia",
                "May cause increased red cell hemolysis & hemolytic anemia in infants with low serum vitamin E concentrations"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "baloxavir marboxil",
            "description": {
                "common": "carbonyl iron will decrease the level or effect of baloxavir marboxil by  cation binding in GI tract. Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "carbonyl iron decreases levels of ciprofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "demeclocycline",
            "description": {
                "common": "carbonyl iron decreases levels of demeclocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxycycline",
            "description": {
                "common": "carbonyl iron decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eltrombopag",
            "description": {
                "common": "carbonyl iron decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fleroxacin",
            "description": {
                "common": "carbonyl iron decreases levels of fleroxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gemifloxacin",
            "description": {
                "common": "carbonyl iron decreases levels of gemifloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levofloxacin",
            "description": {
                "common": "carbonyl iron decreases levels of levofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "minocycline",
            "description": {
                "common": "carbonyl iron decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "moxifloxacin",
            "description": {
                "common": "carbonyl iron decreases levels of moxifloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "carbonyl iron decreases levels of mycophenolate by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Interaction only with oral iron administration."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "carbonyl iron decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxytetracycline",
            "description": {
                "common": "carbonyl iron decreases levels of oxytetracycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tetracycline",
            "description": {
                "common": "carbonyl iron decreases levels of tetracycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aluminum hydroxide",
            "description": {
                "common": "aluminum hydroxide will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "calcium carbonate will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferasirox",
            "description": {
                "common": "deferasirox decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Deferasirox chelates iron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferiprone",
            "description": {
                "common": "carbonyl iron decreases levels of deferiprone by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Deferiprone may bind polyvalent cations (eg, iron, aluminum, and zinc), separate administration by at least 4 hr between deferiprone and other medications (eg, antacids), or supplements containing these polyvalent cations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferoxamine",
            "description": {
                "common": "deferoxamine decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Deferoxamine chelates iron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "delafloxacin",
            "description": {
                "common": "carbonyl iron will decrease the level or effect of delafloxacin by  cation binding in GI tract. Modify Therapy/Monitor Closely. Oral delafloxacin form chelates with alkaline earth and transition metal cations. Administer oral delafloxacin at least 2 hr before or 6 hr after these agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexlansoprazole",
            "description": {
                "common": "dexlansoprazole will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "didanosine",
            "description": {
                "common": "didanosine will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Applies to didanosine chewable tablets and powder for oral solution; administer 2 hr before or several hours after didanosine oral solution or chewable tablet administration"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esomeprazole",
            "description": {
                "common": "esomeprazole will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "famotidine",
            "description": {
                "common": "famotidine will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibandronate",
            "description": {
                "common": "carbonyl iron decreases levels of ibandronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen/famotidine",
            "description": {
                "common": "ibuprofen/famotidine will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lansoprazole",
            "description": {
                "common": "lansoprazole will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levodopa",
            "description": {
                "common": "carbonyl iron decreases levels of levodopa by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Oral administration of iron salts should be separated from levodopa by at least 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "carbonyl iron decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "liothyronine",
            "description": {
                "common": "carbonyl iron decreases levels of liothyronine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methyldopa",
            "description": {
                "common": "carbonyl iron decreases levels of methyldopa by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nizatidine",
            "description": {
                "common": "nizatidine will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omadacycline",
            "description": {
                "common": "carbonyl iron will decrease the level or effect of omadacycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omeprazole",
            "description": {
                "common": "omeprazole will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pantoprazole",
            "description": {
                "common": "pantoprazole will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penicillamine",
            "description": {
                "common": "carbonyl iron decreases levels of penicillamine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Interaction only with oral iron administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabeprazole",
            "description": {
                "common": "rabeprazole will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sarecycline",
            "description": {
                "common": "carbonyl iron will decrease the level or effect of sarecycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium bicarbonate",
            "description": {
                "common": "sodium bicarbonate will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium citrate/citric acid",
            "description": {
                "common": "sodium citrate/citric acid will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium picosulfate/magnesium oxide/anhydrous citric acid",
            "description": {
                "common": "sodium picosulfate/magnesium oxide/anhydrous citric acid decreases levels of carbonyl iron by cation binding in GI tract. Use Caution/Monitor. Take at least 2 hours before and not less than 6 hours after administration of sodium picosulfate, magnesium oxide and anhydrous citric acid to avoid magnesium chelation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer iron products at least 2 hr before and no less than 6 hr after each dose to avoid chelation with magnesium. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer iron products at least 2 hr before and no less than 6 hr after each dose to avoid chelation with magnesium. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thyroid desiccated",
            "description": {
                "common": "carbonyl iron decreases levels of thyroid desiccated by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trientine",
            "description": {
                "common": "trientine, carbonyl iron.\nEither decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hr."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vonoprazan",
            "description": {
                "common": "vonoprazan will decrease the level or effect of carbonyl iron by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium acetate",
            "description": {
                "common": "calcium acetate decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "calcium carbonate decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium chloride",
            "description": {
                "common": "calcium chloride decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium citrate",
            "description": {
                "common": "calcium citrate decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium gluconate",
            "description": {
                "common": "calcium gluconate decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gymnema",
            "description": {
                "common": "gymnema decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "manganese",
            "description": {
                "common": "carbonyl iron decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin E",
            "description": {
                "common": "vitamin E decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Epigastric pain",
            "percent": null
        },
        {
            "name": "Dark stools",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Dark stools",
            "percent": null
        },
        {
            "name": "Hemosiderosis",
            "percent": null
        },
        {
            "name": "during long",
            "percent": null
        },
        {
            "name": "term administration of large amounts",
            "percent": null
        },
        {
            "name": "Urine discoloration",
            "percent": null
        },
        {
            "name": "Dental stain by some formulations",
            "percent": null
        },
        {
            "name": "Heartburn",
            "percent": null
        }
    ]
}